文献速递母胎医学

基于单倍型的甲基丙二酸血症无创产前诊断及与c.609G>A相关的复发性致病单倍型的发现

Haplotype-based noninvasive prenatal diagnosis of methylmalonic acidemia and the discovery of a recurrent pathogenic haplotype associated with c.609G>A.
PubMed 文献 · Prenat Diagn · 2023-11-13

本研究设计了一个161.89kb捕获面板用于富集高杂合SNP,采用相对单倍型剂量(RHDO)和贝叶斯因子推断胎儿基因型,并对41例甲基丙二酸血症(MMA)风险妊娠(中位孕周8+2周)进行无创产前诊断(NIPD),结果与侵入性产前诊断(IPD)全部一致;母源变异检测成功率为92.7%(38/41),结合父源结果后总体成功率达100%(41/41)。研究还发现了一个包含28个SNP的核心单倍型(hap_2),在携带c.609G>A的致病单倍型中显著富集,c.609G>A携带者在这28个SNP中平均有22.38个杂合位点。

要点

  • NIPD-MMA对母源变异检测成功率为92.7%(38/41),结合父源后总体成功率达100%(41/41)。
  • 所有NIPD结果与IPD验证结果一致。
  • 发现包含28个SNP的核心单倍型hap_2在c.609G>A致病单倍型中显著富集。

核心结论

  • NIPD-MMA为早期、准确、安全的产前诊断提供了可行选择。
  • 复发性核心致病单倍型的发现为单倍型定相提供了新方法,并有望在未来实现不依赖先证者的NIPD。

研究设计与样本

  • 研究设计161.89kb捕获面板选择性富集高杂合SNP,采用相对单倍型剂量(RHDO)和贝叶斯因子推断胎儿基因型,并以侵入性产前诊断(IPD)验证。
  • 招募41例甲基丙二酸血症(MMA)风险妊娠,中位孕周8+2周。
  • 基于致病与正常单倍型频率差异鉴定与c.609G>A相关的核心致病单倍型。

主要发现

  • NIPD-MMA对母源变异的检测成功率为92.7%(38/41),结合父源结果后总体成功率达100%(41/41)。
  • 所有NIPD结果与IPD结果一致。
  • 核心单倍型hap_2包含28个SNP,在携带c.609G>A的致病单倍型中显著富集。
  • c.609G>A携带者在这28个SNP中平均有22.38个杂合位点。

关键数值与推荐

  • NIPD-MMA对母源变异检测成功率为92.7%(38/41),结合父源结果后总体成功率为100%(41/41)。
  • 核心单倍型hap_2由28个SNP组成,在c.609G>A致病单倍型中显著富集。
  • c.609G>A携带者在这28个SNP中平均有22.38个杂合位点。

临床怎么用

  • NIPD-MMA可作为早期、准确、安全的产前诊断可行选择。
  • 复发性核心致病单倍型有望在未来实现不依赖先证者的NIPD。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early diagnosis and intervention are crucial for the prognosis of methylmalonic acidemia (MMA). However, research focused on early prenatal diagnosis of MMA is limited. METHODS: A 161.89kb capture panel was designed for selectively enriching highly heterozygous SNPs. Fetal genotypes were inferred using relative haplotype dosage (RHDO) and Bayes factor, followed by invasive prenatal diagnosis (IPD) for validation. A core pathogenic haplotype associated with c.609G>A was identified based on the frequency differences between pathogenic and normal haplotypes. RESULTS: We recruited 41 pregnancies at risk of MMA with a median gestational age of 8+2 weeks. The assay success rate of NIPD-MMA for maternal variants was 92.7% (38/41), and after incorporating the paternal result, the overall assay success rate reached 100% (41/41). All NIPD results were concordant with IPD. Notably, a core haplotype (hap_2), comprising 28 SNPs, demonstrates significant enrichment within pathogenic haplotypes bearing the c.609G>A variation. On average, c.609G>A carriers had 22.38 heterozygous loci within these 28 SNPs. CONCLUSION: NIPD-MMA presents a viable choice for early, accurate, and safe prenatal diagnosis. Furthermore, the discovery of the recurrent core pathogenic haplotype provides a novel approach for haplotype phasing and has the potential for realizing proband-independent NIPD in the future.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Fu X, Li S, Zhao Z, et al. Haplotype-based noninvasive prenatal diagnosis of methylmalonic acidemia and the discovery of a recurrent pathogenic haplotype associated with c.609G>A. Prenat Diagn. 2023. PMID: 37957774. doi:10.1002/pd.6458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。